Congress Materials – Annual Academy of Oncology Nurse and Patient Navigators (AONN 2024)

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

Post-progression and Safety Outcomes With First-line Amivantamab Plus Lazertinib Versus Osimertinib in Patients With Advanced Non-small Cell Lung Cancer With Common EGFR Mutations: Implications for Best Management Practices

Sarah Smith, Alexander I Spira, Danny Nguyen, Seema Sethi, Shirish Gadgeel

 

View poster